Type 2 Diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: This Group is given a Diabetic Diet for 12 weeks That has been used Low-Acid Foods and has been Eliminated of High-Acid Foods in Their Diet. Intervention 2: Contro
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: People with Type 2 Diabetes Over 20 and Under 65 Years Old People with Type 2 Diabetes with Body Mass Index above 18.5
Exclusion criteria
Exclusion criteria: cancer Cushing's Syndrome Taking Glucocorticoids Diabetic Nephropathy Respiratory Diseases such as: Chronic Obstructive Pulmonary Disease Pregnancy and Lactation Enetral and Parenteral Feeding Use Insulin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting Blood Sugar Concentration. Timepoint: Measurement of Fasting Blood Sugar Concentration at Baseline and 12 Weeks Later. Method of measurement: Biochemical Testing to Measure Fasting Blood Sugar. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum hemoglobin A1C Concentration. Timepoint: Serum Concentration of Hemoglobin A1C Measurement at Baseline and 12 Weeks Later. Method of measurement: Biochemistry Test to Measure Serum Concentration of Hemoglobin A1C.;Serum Concentration of Insulin. Timepoint: Measurement of Serum Insulin Concentration at Baseline and 12 Weeks Later. Method of measurement: Biochemistry Test to Measure Serum Concentration of Insulin.;Quantitative Insulin Sensitivity Check Index(QUICKI). Timepoint: Measurement of Insulin Sensitivity Index at Baseline and 12 Weeks Later. Method of measurement: Using the Quantitative Insulin Sensitivity Check Index(QUICKI).;Blood Pressure. Timepoint: Measurement of Blood Pressure at Baseline and 12 Weeks Later. Method of measurement: Using Mercury Barometer.;Serum Concentration of Lipid Profile (Total Cholesterol, Low Density Lipoprotein, High Density Lipoprotein, Triglyceride). Timepoint: Measurement of Serum Concentration of Lipid Profile (Total Cholesterol, Low Density Lipoprotein, High Density Lipoprotein, Triglyceride) at Baseline and 12 Weeks Later. Method of measurement: Biochemistry Test to Measure Serum Concentration of Lipid Profile.;Insulin Resistance Index (Homeostasis Model Assessment (HOMA)). Timepoint: Measurement of Insulin Resistance Index at Baseline and 12 Weeks Later. Method of measurement: Using the Hemostasis Model Assessment Formula (HOMA). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Seyed Mohammad Hossein Rouhani
Esfahan University of Medical Sciences
Outcome results
None listed